Celularity Statistics
Total Valuation
Celularity has a market cap or net worth of $59.52 million. The enterprise value is $126.68 million.
Important Dates
The last earnings date was Friday, August 29, 2025, after market close.
Earnings Date | Aug 29, 2025 |
Ex-Dividend Date | n/a |
Share Statistics
Celularity has 26.69 million shares outstanding. The number of shares has increased by 12.89% in one year.
Current Share Class | 26.69M |
Shares Outstanding | 26.69M |
Shares Change (YoY) | +12.89% |
Shares Change (QoQ) | +2.08% |
Owned by Insiders (%) | 12.14% |
Owned by Institutions (%) | 13.14% |
Float | 13.70M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | 1.11 |
Forward PS | n/a |
PB Ratio | n/a |
P/TBV Ratio | n/a |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | 2.84 |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.25
Current Ratio | 0.25 |
Quick Ratio | 0.17 |
Debt / Equity | n/a |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | -5.96 |
Financial Efficiency
Return on equity (ROE) is -6,367.24% and return on invested capital (ROIC) is -42.33%.
Return on Equity (ROE) | -6,367.24% |
Return on Assets (ROA) | -23.14% |
Return on Invested Capital (ROIC) | -42.33% |
Return on Capital Employed (ROCE) | -92.74% |
Revenue Per Employee | $362,520 |
Profits Per Employee | -$598,935 |
Employee Count | 123 |
Asset Turnover | 0.35 |
Inventory Turnover | 5.47 |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -22.58% in the last 52 weeks. The beta is 0.81, so Celularity's price volatility has been lower than the market average.
Beta (5Y) | 0.81 |
52-Week Price Change | -22.58% |
50-Day Moving Average | 3.00 |
200-Day Moving Average | 2.19 |
Relative Strength Index (RSI) | 34.91 |
Average Volume (20 Days) | 136,236 |
Short Selling Information
The latest short interest is 1.69 million, so 6.33% of the outstanding shares have been sold short.
Short Interest | 1.69M |
Short Previous Month | 1.63M |
Short % of Shares Out | 6.33% |
Short % of Float | 12.32% |
Short Ratio (days to cover) | 24.22 |
Income Statement
In the last 12 months, Celularity had revenue of $44.59 million and -$73.67 million in losses. Loss per share was -$3.21.
Revenue | 44.59M |
Gross Profit | 24.57M |
Operating Income | -47.35M |
Pretax Income | -196.29M |
Net Income | -73.67M |
EBITDA | -39.91M |
EBIT | -47.35M |
Loss Per Share | -$3.21 |
Full Income Statement Balance Sheet
The company has $863,000 in cash and $70.15 million in debt, giving a net cash position of -$69.29 million or -$2.60 per share.
Cash & Cash Equivalents | 863,000 |
Total Debt | 70.15M |
Net Cash | -69.29M |
Net Cash Per Share | -$2.60 |
Equity (Book Value) | -25.50M |
Book Value Per Share | -1.04 |
Working Capital | -51.96M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was -$2.54 million and capital expenditures -$91,000, giving a free cash flow of -$2.63 million.
Operating Cash Flow | -2.54M |
Capital Expenditures | -91,000 |
Free Cash Flow | -2.63M |
FCF Per Share | -$0.10 |
Full Cash Flow Statement Margins
Gross margin is 55.10%, with operating and profit margins of -106.19% and -165.21%.
Gross Margin | 55.10% |
Operating Margin | -106.19% |
Pretax Margin | -165.21% |
Profit Margin | -165.21% |
EBITDA Margin | -89.51% |
EBIT Margin | -106.19% |
FCF Margin | n/a |
Dividends & Yields
Celularity does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -12.89% |
Shareholder Yield | -12.89% |
Earnings Yield | -128.37% |
FCF Yield | -4.59% |
Analyst Forecast
The average price target for Celularity is $6.00, which is 169.06% higher than the current price. The consensus rating is "Strong Buy".
Price Target | $6.00 |
Price Target Difference | 169.06% |
Analyst Consensus | Strong Buy |
Analyst Count | 1 |
Revenue Growth Forecast (5Y) | n/a |
EPS Growth Forecast (5Y) | n/a |
Stock Forecasts Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
Lynch Fair Value | n/a |
Lynch Upside | n/a |
Graham Number | n/a |
Graham Upside | n/a |
Stock Splits
The last stock split was on February 29, 2024. It was a reverse split with a ratio of 1:10.
Last Split Date | Feb 29, 2024 |
Split Type | Reverse |
Split Ratio | 1:10 |
Scores
Celularity has an Altman Z-Score of -12.23 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
Altman Z-Score | -12.23 |
Piotroski F-Score | 2 |